Health Catalyst (NASDAQ:HCAT) General Counsel Sells $72,402.00 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 27,425 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $2.64, for a total value of $72,402.00. Following the completion of the sale, the general counsel owned 100,000 shares in the company, valued at approximately $264,000. This trade represents a 21.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Health Catalyst Stock Down 1.1%

Shares of HCAT stock traded down $0.03 on Tuesday, hitting $2.61. 493,261 shares of the stock were exchanged, compared to its average volume of 704,965. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $184.61 million, a P/E ratio of -1.64 and a beta of 1.72. Health Catalyst, Inc. has a fifty-two week low of $2.02 and a fifty-two week high of $8.52. The business has a 50-day moving average of $2.83 and a 200 day moving average of $3.30.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Monday, November 10th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.05 by $0.01. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%.The firm had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $75.05 million. Equities analysts anticipate that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Institutional Investors Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently modified their holdings of HCAT. First Light Asset Management LLC boosted its position in shares of Health Catalyst by 99.1% in the first quarter. First Light Asset Management LLC now owns 10,436,807 shares of the company’s stock valued at $47,279,000 after acquiring an additional 5,195,686 shares during the period. Whetstone Capital Advisors LLC acquired a new stake in Health Catalyst in the 1st quarter worth about $7,724,000. Millennium Management LLC boosted its holdings in Health Catalyst by 2,513.3% in the 3rd quarter. Millennium Management LLC now owns 1,589,536 shares of the company’s stock valued at $4,530,000 after purchasing an additional 1,528,710 shares during the period. Nuveen LLC acquired a new position in shares of Health Catalyst during the 1st quarter worth approximately $2,674,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Health Catalyst by 172.6% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 694,361 shares of the company’s stock worth $3,145,000 after purchasing an additional 439,599 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on HCAT shares. Weiss Ratings restated a “sell (e+)” rating on shares of Health Catalyst in a report on Monday. Piper Sandler cut shares of Health Catalyst from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $8.00 to $4.00 in a research report on Wednesday, August 27th. Wells Fargo & Company dropped their price objective on shares of Health Catalyst from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Summit Redstone set a $5.00 target price on shares of Health Catalyst in a research note on Friday, August 29th. Finally, Citigroup reduced their target price on shares of Health Catalyst from $3.50 to $3.25 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Five analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $4.36.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.